Skip to Content

Generic Anjeso Availability

Last updated on Sep 8, 2021.

Anjeso is a brand name of meloxicam, approved by the FDA in the following formulation(s):

ANJESO (meloxicam - solution;intravenous)

  • Manufacturer: BAUDAX
    Approval date: February 20, 2020
    Strength(s): 30MG/ML (30MG/ML) [RLD]

Has a generic version of Anjeso been approved?

No. There is currently no therapeutically equivalent version of Anjeso available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Anjeso. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Patent 10,463,673

    Patent expiration dates:

    • February 24, 2024
      ✓ 
      Patent use: MANAGEMENT OF MODERATE-TO-SEVERE PAIN BY INTRAVENOUS INJECTION
      ✓ 
      Drug product
  • Patent 10,471,067

    Patent expiration dates:

    • February 24, 2024
      ✓ 
      Patent use: MANAGEMENT OF MODERATE-TO-SEVERE PAIN BY INTRAVENOUS INJECTION
      ✓ 
      Drug product
  • Patent 10,709,713

    Patent expiration dates:

    • May 26, 2030
      ✓ 
      Patent use: MANAGEMENT OF MODERATE-TO-SEVERE PAIN BY INTRAVENOUS INJECTION
  • Patent 10,881,663

    Patent expiration dates:

    • March 8, 2039
      ✓ 
      Patent use: MANAGEMENT OF MODERATE-TO-SEVERE PAIN BY INTRAVENOUS INJECTION IN PATIENTS WITH MILD RENAL IMPAIRMENT
  • Nanoparticulate meloxicam formulations
    Patent 8,512,727
    Issued: August 20, 2013
    Assignee(s): Alkermes Pharma Ireland Limited

    The present invention is directed to nanoparticulate compositions comprising meloxicam. The meloxicam particles of the composition have an effective average particle size of less than about 2000 nm.

    Patent expiration dates:

    • December 25, 2022
      ✓ 
      Patent use: MANAGEMENT OF MODERATE-TO-SEVERE PAIN BY INTRAVENOUS INJECTION
      ✓ 
      Drug product
  • Reduction of flake-like aggregation in nanoparticulate active agent compositions
    Patent 9,974,746
    Issued: May 22, 2018
    Assignee(s): Alkermes Pharma Ireland Limited

    This invention is directed to reduction of flake-like aggregation in nanoparticulate compositions. Also encompassed by the invention are compositions comprising a nanoparticulate active agent, at least one surface stabilizer and a flake-like aggregation reducing agent, such as a buffer and a sugar. The nanoparticulate active agent compositions comprise particles of the active agent having an effective average particle size of less than about 2000 nm.

    Patent expiration dates:

    • May 26, 2030
      ✓ 
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:

    • February 20, 2023 - NEW PRODUCT

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.